BN vs JPM

The deterministic health scores present a mixed picture: the Piotroski F-Score of 4/9 indicates borderline stable financial health, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite a high forward P/E of 8.04 suggesting reasonable future earnings expectations, the trailing P/E of 131.03 reflects significant volatility or one-time impacts. Earnings growth is highly volatile with a YoY surge of 719.20%, but recent quarters show deteriorating performance, including a -91.3% YoY EPS drop and consistent earnings misses. The stock trades well above the Graham Number of $12.39 and intrinsic value of $10.62, implying substantial premium pricing based on growth and market sentiment rather than defensive or fundamental value.

JPM shows bullish fundamentals based on deterministic rules. Financial strength is weak (F-Score 2/9). Key strengths include strong valuation and growth metrics. Price trades at a 109.8% premium to fair value estimate ($140.21), limiting near-term upside from a valuation perspective.